AUGMENTIN ES - THE DRUG WITH THE ADVANCED PHARMACOKINETICS


Дәйексөз келтіру

Толық мәтін

Аннотация

The present article is concerned with inhibitor-protected antibiotic Amoxicillin/Klavulanat (Augmentin) with high efficiency in the treatment of infections of respiratory tract, soft tissues and urinary system. Currently, the most preparations of Amoxicillin/Klavulanat were developed with component ratio 4: 1, however experimental and clinical researches have shown benefits of "advanced" preparations with higher component ratio, in particular 16: 1 (Augmentin XR) and 14: 1 - a pediatric syrup Augmentin ES. It was shown that Augmentin ES is effective in the treatment of acute otitis media, particularly in otitis caused by pneumococci with the decreased sensitivity, as well as caused by β-lactamase - producing H. influenzae and M. catarrhalis. The preparation is effective in the treatment of acute bacterial sinusitis caused by the same flora, and in the treatment of other infections, for example caused by staphilococci with higher minimal inhibitory concentration in relation to Amoxicillin.

Авторлар туралы

V Tatochenko

Vladimir Tatochenko

Әдебиет тізімі

  1. Reading C, Cole M. Clavulanic acid: a β-lactamaseinhibiting β-lactam from Streptomyces clavuligerus. Antimicrobial Agents and Chemotherapy 1977;11:852-57.
  2. Comber KR, Horton R, Mizen L, et al. Activity of amoxicillin/clavulanic acid (2 : 1) [BRL 25000, Augmentin] in vitro and in vivo. In Current Chemotherapy and Infectious Disease. Proceedings of the Eleventh International Congress of Chemotherapy and the Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. 1980:343-344. American Society for Microbiology, Washington, DC, USA.
  3. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996;25:213-17.
  4. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:29-34.
  5. Bowker KE, Noel AR, MacGowan AP. The magnitude of the pharmacodynamic (pD) index which determines outcome with amoxicillin/clavulanate is similar for Streptococcus pneumoniae (Sp) and Haemophilus influenzae (Hi) and not dependent on inoculum. In Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL 2003. Abstract A1158, p. 16. American Society for Microbiology, Washington, DC, USA.
  6. Cooper CE, Slocombe B, White AR. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxicillin against β-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 1990;26:371-80.
  7. Jacobs MR. (2003). How can we predict bacterial eradication? International Journal of Infectious Diseases 2003;7(Suppl. 1):S13-20.
  8. Berry V, Singley C, Satterfield J, et al. Efficacy of pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection in rats caused by Haemophilus influenzae. In Abstracts of the Twelfth Euroean Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 2002. Clin Microbiol Infect 2002;8(Suppl. 1):abstr. P1375, P322.
  9. White1 AR, Kayel C, Poupard Jб et al. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrobial Chemother 2004;53(Suppl. S1):i3-i20.
  10. Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Inf Dis J 2000;19:95-104.
  11. Dagan R. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int J Infect Dis 2003;7:S2I-S26.
  12. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001;20(9):829-37.
  13. Hoberman A, Dagan R, Leibovitz E, et al. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Inf Dis J 2005;24(6):525-32.
  14. Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics 2009;124(1):9-16.
  15. Behre U, Burrow H-M, Quinn P, et al. Efficacy of twice daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection 1997;25:163-66.
  16. Damrikarnlert L, Jauregui AC, Kzadri M. et al. Efficacy and safety of amoxycillin/clavulanate (Augmentin®) twice daily versus three times daily in the treatment of acute otitis media in children. J Chemother 2000;12:79-87.
  17. Hoberman A, Paradise JL, Burch DL, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin®) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997;16:463-70.
  18. Bottenfield GW, Burch DJ, Hedrick JA, et al. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998;17:963-68.
  19. World Health Organization. WHO Model Prescribing Information. Drugs used in bacterial infections. WHO, Geneva, Switzerland 2001.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2010

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>